Thank you to all of those who submitted abstracts to the 21st Symposium.
The program has been finalized and is posted below. (The program is also available by PDF file here).
We hope to see you and your colleagues in Washington D.C. in October!

Cosponsored by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group,
Myoclonus Study Group, Tourette Syndrome Study Group, Cooperative Ataxia Group,
Tremor Research Group, and The Movement Disorder Society

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of The Movement Disorder Society and The Parkinson Study Group.  The Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

The Symposium will consist of peer-reviewed platform and poster presentations designed to communicate recent research advances in the field of Parkinson’s disease, Huntington’s disease, ataxia, dystonia, myoclonus, Tourette’s syndrome, tremor and other Movement Disorders to professionals in neurology and related disciplines.  Practitioners, educators, and researchers are invited to attend.  Abstracts of platform and poster presentations representing original material will be published in the September 2007 issue of Movement Disorders.
 
At the conclusion of this session, participants should be able to: 1) Identify by scholarly review, oral presentation and group discussion the current research into the diagnosis, prevention and treatment of Parkinson’s disease and other Movement Disorders; 2) Identify the important advances in research and clinical treatments relating to a variety of Movement Disorders; 3) Discuss new pharmacological and non-pharmacological treatment options available for Parkinson’s disease and other Movement Disorders; 4) Identify the mechanisms (genetic, environmental, pathophysiology, neurobiology) linked to Parkinson’s disease and other Movement Disorders; and 5) Discuss the diagnostic approaches and tools available for Parkinson’s disease and other Movement Disorders.

Parkinson’s disease Session: 8:15 AM – 10:15 AM
This session consists of a keynote speaker and 4 presentations by the following individuals with allotted time for questions and answers after each presenter.

8:15 AM-8:30 AM
Introduction and acknowledgements by Andrew Siderowf, MD, MSCE, Chair, PSG Symposia Committee

8:30-9:15 AM
KEYNOTE ADDRESS:  Parkinson’s Interrupted: Epidemiology and Disease Progression
Alberto Ascherio, MD, PhD.  Harvard School of Public Health, Boston, MA, USA.

9:15-9:30 AM
Atomoxetine for the Treatment of Executive Dysfunction in Parkinson’s Disease: A Pilot Open-Label Study
 L. Marsh,1 S.S. Bassett,1 K. Biglan,2 M. Gerstenhaber,1 J.R. Williams.3  1Johns Hopkins University School of Medicine, Baltimore, MD; 2University of Rochester School of Medicine, Rochester, NY; 3Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.

9:30-9:45 AM
Montreal Cognitive Assessment (MoCA) Performance in Parkinson’s Disease Patients with Intact Cognition by Mini-Mental State Examination (MMSE) Score
S. Nazem, P. Moberg, J. Duda, T. Ten Have, H. Hurtig, M. Stern, D. Weintraub.  University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

9:45-10:00 AM
Combined Effects of Smoking, Coffee, and NSAIDs on Parkinson's Disease Risk
K. M. Powers,1 D. M. Kay,2  S. A. Factor,3,4  C. P. Zabetian,5,6  D. Higgins,4  A. Samii,6,7 J. G. Nutt,8  A. Griffith,9  B. Leis,9  J. W. Roberts,10  E. D. Martinez,5,6  J. S. Montimurro,2  H. Checkoway,1  H. Payami.2  1University of Washington, School of Public Health and Community Medicine, Department of Environmental and Occupational Health Sciences, Seattle, WA; 2Genomics Institute, New York State Department of Health, Wadsworth Center, Albany, NY; 3Department of Neurology, Emory University School of Medicine, Atlanta, GA;. 4Parkinson’s Disease and Movement Disorder Clinic, Albany Medical Center, Albany, NY; 5Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle WA; 6Department of Neurology, University of Washington School of Medicine, Seattle, WA; 7Parkinson’s Disease Research Education and Clinical Center, VA Puget Sound Health care System, Seattle, WA; 8Department of Neurology, Oregon Health & Science University, Portland, OR; 9Booth Gardner Parkinson’s Care Center, Evergreen Hospital Medical Center, Kirkland, WA; 10Virginia Mason Medical Center, Seattle, WA, USA.

10:00-10:15 AM  
LATE-BREAKING RESEARCH
Financial Anatomy of Parkinson Research
E.R. Dorsey,1 J.P. Thompson,1 S. Nicholson,2 B. Fiske,3 T. Sherer,3 M. Frasier,3 1University of Rochester Medical Center, Rochester, NY; 2Cornell University, Ithaca, NY; 3Michael J. Fox Foundation, New York, NY, USA.

10:15-10:45 AM
BREAK/Poster viewing

Other Movement Disorders Session: 10:45 AM – 12:30 PM
This session consists of a keynote speaker and 4 presentations by the following individuals with allotted time for questions and answers after each presenter.

10:45-11:30 AM
KEYNOTE ADDRESS:  Spinocerebellar Ataxia Type 10
Tetsuo Ashizawa, MD, University of Texas Medical Branch at Galveston, Galveston, TX, USA.

11:30-11:45 AM 
Huntington’s Disease Phenotype with CAG Expansion Less Than 36
H. Fadil, R. Zweig. Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.

11:45-12:00 PM
Brain Networks in Tourette’s Syndrome With and Without OCD: An FDG PET Study
M. Pourfar, M. Carbon-Correll, N. Brown, C. Budman, D. Eidelberg, A. Feigin.  The Feinstein Institute for Medical Research, North Shore University Health System, Manhasset, New York, USA.

12:00-12:15 PM
Huntingtin Aggregation in Motor Neurons: Two Huntington’s Disease Patients Who Developed Motor Neuron Disease
E. Coon, P Kirby, W. Martin, M. Wieler, A. Osmand, H. Paulson.  University of Iowa Medical School, Iowa City, IA, USA.

12:15-12:30 PM 
LATE-BREAKING RESEARCH
The “Depression Phenotype” in Pre-Diagnosed Huntington’s Disease
K. Duff,1 J.S. Paulsen,1 L.J. Beglinger,1 J.C. Stout,2 D.R. Langbehn,1 C. Wang,2 S. Queller,2 N.E. Carlozzi,2 & the PREDICT-HD Investigators of the Huntington Study Group.  1University of Iowa, Iowa City, IA, USA; 2University of Indiana, Bloomington, IN, USA.
  
12:30-12:45 PM
Presentation of best abstract awards and closing remarks by Jang-Ho Cha, MD, PhD, Chair, HSG Symposia Committee.

POSTER SESSION: 12:45-1:45 PM
This session consists of guided tours of the posters by Dr. Andrew Siderowf, Chair of the PSG Symposia Committee and Dr. Jang-Ho Cha, Chair of the OMD Symposia Committee with abstract authors presenting their research.

Poster 1 (OMD)
Effects of Dopamine Agonist Treatment on Spinal Cord Excitability in Patients with Restless Legs Syndrome
W. Bara-Jimenez,1,2,3 M. Aksu,1,4 F.E. Leon-Sarmiento,1,5 M.F. Malone,1 R.Y.K. Lai,6 B.A. Chizh,7 K. Maltby,7 M. Hallett,2 T.N. Chase.1  1Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; 2Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; 3Bethesda Neuroscience Clinic, Bethesda, MD, USA; 4Neurology Department, Erciyes University, Kayseri, Turkey; 5Uniciencia Research Group, Universidad Nacional/Fundacion Santa Fe, Bogota, Colombia; 6Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK; 7Cambridge Clinical Unit, GlaxoSmithKline, Cambridge, Cambridgeshire, UK.

Poster 2 (OMD)
Histones Associated with Downregulated Genes are Hypo-Acetylated in Huntington’s Disease Models
G. Sadri-Vakili,1  B. Bouzou,2 C.L. Benn,1 M.-O. Kim,1 P. Chawla,1 R.P. Overland,1 K.E. Glajch,1 E. Xia,1 Z. Qiu,1 S.M. Hersch,1 T.W. Clark,2 G.J. Yohrling,3 J.-H.J. Cha.1   1MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA; 2Center for Interdisciplinary Informatics, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA; 3Johnson & Johnson Pharmaceuticals, Research & Development, L.L.C., Spring House, PA, USA.

Poster 3 (OMD)
Suppression of Polyglutamine Neurotoxicity byC-terminus of Hsp70 Interacting Protein (CHIP) Supports an Aggregation Model for Polyglutamine Disease Pathogenesis
A.J. Williams,1 T.M. Knutson,1 V.F. Colomer Gould,2 A.P. Osmand,3 H.L. Paulson.1  1University of Iowa, Iowa City, IA; 2Johns Hopkins University, Baltimore, MD; 3University of Tennessee-Knoxville, Knoxville, TN, USA.

Poster 4 (OMD)
Anterocollis: Classification, Clinical Phenotype, Treatment Outcomes and Risk Factors
A. Tuchman, C. Sengun, A. Russell, C. Singer, S. Papapetropoulos.  Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, USA.

Poster 5 (OMD)
Mutant Huntingtin-Mediated Histone Monoubiquitylation Induces Transcriptional Dysregulation in Huntington’s Disease
M.O. Kim, P. Chawla, R.P. Overland, G. Sadri-Vakili, and J.H. Cha.  MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.

Poster 6 (PD)
Does the Burden of Psychiatric Symptoms Vary Across Stages of Parkinson’s Disease?
K.E. Anderson,1 A.L. Gruber-Baldini,2 J. Mullins,3 P.S. Fishman,3 S.G. Reich,3 W.J. Weiner,3 L.M. Shulman.3  1University of Maryland, Department of Neurology, Maryland Parkinson’s and Movement Disorders Center, Baltimore, MD & University of Maryland, Department of Psychiatry, Baltimore, MD; 2University of Maryland, Department of Epidemiology & Preventive Medicine, Baltimore, MD; 3University of Maryland, Department of Neurology, Maryland Parkinson’s and Movement Disorders Center, Baltimore, MD, USA.

Poster 7 (PD)
Treatment of Nocturnal Symptoms of Parkinson’s Disease Using Rotigotine Transdermal Patch
R. Chaudhuri,1 J. Jankovic,2 C. Trenkwalder,3 B. Boroojerdi.4  1King’s College Hospital, London, UK; 2Baylor College of Medicine, Houston, TX, USA; 3Paracelsus-Elena Hospital, Kassel, Germany; 4SCHWARZ Biosciences, Monheim, Germany.

Poster 8 (PD)
Lipids and Alpha-Synuclein Aggregation in Parkinson’s Disease
K. Broersen, B. Davletov.  Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.

Poster 9 (PD)
Concentrations of Tetrahydroisoquinolines in Common Fruits and Vegetables
M. DeCuypere,1 D. D. Miller,2 M.S. LeDoux.1  1University of Tennessee Health Science Center, Department of Neurology;  2University of Tennessee Health Science Center, Department of Pharmaceutical Sciences, Memphis, TN, USA.

Poster 10 (PD)
The Pivotal Role of Nitric Oxide in 6-OHDA-induced Dopaminergic Neurotoxicity: Neurochemical Evidences in Rats
V. DiMatteo,1 M. Pierucci,1 A. Benigno,2 G. Crescimanno,2 E. Esposito,1 G. DiGiovanni.2   1Istituto di Ricerche Farmacologiche “Mario Negri”, Consorzio “Mario Negri” Sud, Santa Maria Imbaro (Chieti), Italy; 2Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, “G. Pagano”, Università degli Studi di Palermo, Palermo, Italy.

Poster 11 (PD)
Re-evaluating Dose Conversions When Switching Between Dopamine Agonists: A Post Hoc Analysis of Subjects Initiating Rotigotine Therapy after Prior Maintenance on Ropinirole
C. Bretzmann, A.Eggert.  SCHWARZ Pharma, Mequon, WI, USA.

Poster 12 (PD)
Predicting Falls in Parkinson’s Disease using Functional Reach
S.E. Grill,1 W.F. Rosenberger.2   1Parkinson’s & Movement Disorders Center of Maryland, Elkridge, MD and  Johns Hopkins University, Baltimore, MD; 2George Mason University, Fairfax, VA,USA.

Poster 13 (PD)
Rotigotine Transdermal Patch is Effective in the Treatment of Idiopathic RLS: Results of a 6-Month, Multi-Center, Double Blind, Placebo-Controlled Trial in the USA
W.A. Hening on behalf of the SP792 Study Group.  University of Medicine and Dentistry of New Jersey-Robert Wood Johnson, New Brunswisk, NJ, USA.

Poster 14 (PD)
Voxel-Based Morphometry and Diffusion Tensor Imaging in Parkinson’s Disease
S. Lehericy,1 M. Luciana,2 A. T. Karagulle Kendi,3 K. Ugurbil,3 P. Tuite.4   1Center for NeuroImaging Research (CENIR), INSERM U610, Pitie-Salpetriere Hospital, University Pierre and Marie Curie – Paris 6, Paris, France;
2Department of Psychology, University of Minnesota, USA; 3Center for Magnetic Resonance Research (CMRR), Department of Radiology, University of Minnesota, USA; 4Department of Neurology, University of Minnesota, USA.

Poster 15 (PD)
Assessing Apathy with the UPDRS:  Comparison to the Apathy Evaluation Scale
L. Kirsch-Darrow,1 L. Zahodne,1 B. Skoblar,1 C. Hass,3 C. Jacobson,2 M.S. Okun,2 H.H. Fernandez,2 R. Rodriquez,2 D. Bowers.1,2   1Department of Clinical and Health Psychology, University of Florida, Gainesville, FL; 2Department of Neurology, University of Florida, Gainesville, FL; 3Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL, USA.

Poster 16 (PD)
The Relationship Between Non-motor Symptoms, Disease Severity, and Motor Subtype in Parkinson’s Disease
S. Lessig, D. Song, E. Tecoma, and J. Corey-Bloom.  Department of Neurosciences at Veterans Affairs San Diego Healthcare System and University of California, San Diego, California, USA.

Poster 17 (PD)
The Washington Parkinson Disease Registry (WPDR): A State-Wide Research Registry
H.M. Kim,1,2 A. Samii,1,2 E. Martinez,1,3 G. Richards,1,3 C. Zabetian,1,3 J.B. Leverenz.1,2,4  1Department of Neurology, University of Washington, Seattle, WA; 2Northwest Parkinson's Disease Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA; 3Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA; 4Mental Illness Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA.

Poster 18 (PD)
Diagnosing Depression in Parkinson’s Disease: BDI Screening versus DSM-IV-TR Criteria
B.E. Levin, H. Katzen, D. Nation, B. Scanlon, D. Wilensky, S. Papapetropoulos, C. Singer. C. Sengun, R. Rodriguez.   Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, USA.

Poster 19 (PD)
Neuropsychological Deficits in Parkinson’s Disease Patients Without Global Cognitive Impairment
E. Mamikonyan, P. Moberg, J. Duda, T. Ten Have, H. Hurtig, M. Stern, D. Weintraub.University of Pennsylvania, School of Medicine, Philadelphia, PA, USA.

Poster 20 (PD)
Perceived Driving Ability of Drivers with Parkinson’s Disease
D.P. McCarthy,1 C. Garvin,2 D.N. Lanford,1 M.S. Okun,2 R.L. Rodriguez,2 J. Romrell,2 W.C. Mann,1 S. Bridges,2  H.H. Fernandez.2 1National Older Driver Research and Training Center, University of Florida Gainesville, FL; 2Movement Disorders Center, University of Florida, Gainesville, FL, USA.

Poster 21 (PD)
Rotigotine Patch is Effective in the Treatment of Idiopathic RLS: Results of a 6-Month, Multi-Center, Double Blind, Placebo Controlled Trial in Europe
W. Oertel.  Philipps University, Marburg, Germany.

Poster 22 (PD)
Adjunctive Ropinirole 24-hour Prolonged Release Reduces “Off” Time and Improves the Cardinal Symptoms of Tremor, Rigidity, and Bradykinesia in Patients with Advanced Parkinson’s Disease (PD)
R. Pahwa,1 N Stover,2 N. Earl.3  1University of Kansas Medical Center, Kansas City, KS; 2Department of Neurology, University of Alabama, Birmingham, AL; 3GlaxoSmithKline, Research Triangle Park, NC, USA.

Poster 23 (PD)
A Rating Instrument for Hallucinations in Parkinson’s Disease: The University of Miami Hallucinations Questionnaire (UMHQ.v1)
S. Papapetropoulos,1 C. Sengun,1 C.Singer,1 A. Schrag,2 B. Scanlon,1 J. Ledon,1 H.K. Katzen,1 B.E. Levin.1  1Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, USA; 2Royal Free and University College Medical School, University College, London, UK.

Poster 24 (PD)
Anxiety Disorders in Parkinson’s Disease
G. Pontone, E. Hirsh, K. Anderson, G. Chase, S. Goldstein, S. Grill, S. Lehmann, J. Little, R. Margolis, PV Rabins, H. Weiss, J.R. Williams, L. Marsh.  Johns Hopkins University, Baltimore, MD, USA.

Poster 25 (PD)
Sitting Apraxia in Progressive Supranuclear Palsy
S.G. Reich, W.J. Weiner.  University of Maryland School of Medicine, Department of Neurology, Baltimore, MD, USA.

Poster 26 (PD)
Association of Mid-Life Physical Activity with Risk of Future Parkinson’s Disease
G.W. Ross.1-5 R.D. Abbott,4-8 H. Petrovitch,1-5 C.M. Tanner,9 J. Popper,1,2 A. McMurtray,2,5 K. Masaki, 3-5 L. Launer,10 L.R. White.1-5   1Veterans Affairs Pacific Islands Health Care System, Honolulu, HI; 2Departments of Medicine and 3Geriatrics University of Hawaii John A. Burns School of Medicine, Honolulu, HI; 4Pacific Health Research Institute, Honolulu, HI; 5Kuakini Medical Center/ Honolulu-Asia Aging Study, Honolulu, HI; 6Division of Biostatistics and Epidemiology, University of Virginia School of Medicine, Charlottesville, VA; 7Department of Health Sciences, Shiga University of Medical Science, Otsu, Japan; 8Japan Society for the Promotion of Science; 9The Parkinson’s Institute, Sunnyvale, CA; 10National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Poster 27 (PD)
Statin Use and the Risk of Parkinson’s Disease
M. Etminan,1 B.C. Carleton,2 A. Samii.3  1Center for Clinical Epidemiology and Evaluation, Vancouver Hospital and University of British Columbia, Vancouver, BC, Canada; 2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 3University of Washington School of Medicine, Seattle, WA Parkinson Disease Research Education and Clinical center (PADRECC), Seattle, WA, USA.

Poster 28 (PD)
HFE Variants C282Y and H63D Do Not Alter Risk of Parkinson’s Disease
H.M. Kim,1, 2 A. Samii,1, 2 S.A. Factor,3 A. Griffith,4 J.W. Roberts,5 A.D. Mosley,4 B.C. Leis,4 D. Yearout,1, 11 C.M. Hutter,6 K.L. Edwards,6 G. Richards, 1, 11 J.G. Nutt,7, 8 D.S. Higgins,9 H. Payami,10 C.P. Zabetian.1, 11  1Department of Neurology, University of Washington, Seattle, WA; 2Northwest Parkinson's Disease Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA; 3 Department of Neurology, Emory University School of Medicine, Atlanta, GA; 4Booth Gardner Parkinson's Care Center, Evergreen Hospital Medical Center, Kirkland, WA; 5 Department of Neurology, Virginia Mason Medical Center, Seattle, WA; 6Department of Epidemiology, University of Washington, Seattle, WA; 7 Department of Neurology, Oregon Health and Science University, Portland, OR; 8 Northwest Parkinson's Disease Research Education and Clinical Center, Portland VA Medical Center, Portland, OR; 9Department of Neurology, Albany Medical Center, Albany, NY; 10Wadsworth Center, New York State Department of Health, Albany, NY; 11Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA.

Poster 29 (PD)
Safinamide Treatment Improves Cognition in Parkinson’s Disease
T. Sharma,1 F. Stocchi,2 A.H. Schapira,3 R. Borgohain,4 P. Lorenzana,5 M. Onofrj,6 S. Rossetti,7 S. De Santi,8 R. Anand,9 015 Study Group.  1Cognition Group, Delaware, USA; 2San Raffaele Hospital, Rome, Italy; 3Royal Free Hospital, London, UK; 4Nizam’s Institute, Hyderabad, India; 5Universidad Nacional, Bogota, Colombia; 6Chieti-Pescara University, Italy ; 7Newron Pharmaceuticals, Bresso, Italy; 8NYU School of Medicine, NY, USA; 9APC, Basel, CH.

Poster 30 (PD)
Evaluation of Olfaction and Personality Traits in 1st Degree Relatives of PD Patients
C. Mullin,1 J. Connolly,1 D. Jennings,2 A. Siderowf,1 D. Weintraub,1 K. Marek,2 M. Stern.1 1University of Pennsylvania, Philadelphia, PA; 2Institute for Neurodegenerative Disorders, New Haven, CT, USA.

Poster 31 (PD)
The Contribution of Apathy to Global Cognitive Status in Parkinson’s Disease
B.M. Skoblar, A.E. Mikos, A. Nisenzon, L. Kirsch-Darrow, M.S. Okun, H.H. Fernandez, D. Bowers.  University of Florida, Gainesville, FL, USA.

Poster 32 (PD)
Dystonia in Parkinson’s Disease
A.V.Srinivasan, S.Arunan, M.Jawahar, V.Kannan, M.Haris.  Institute Of Neurology, Government General Hospital and Madras Medical College, Chennai, Tamil Nadu, India.

Poster 33 (PD)
The Relationship between Depression and Incident Dementia in Parkinson’s Disease
L.M. Swearengin, J.R. Williams, L. Marsh.  Johns Hopkins University, Baltimore, MD, USA.

Poster 34 (PD)
Improvements over 24 Months in Patients with Moderate to Severe Idiopathic Restless Legs Syndrome Treated with a Rotigotine Transdermal Patch: Results from a Multi-National, Multi-Centre, Open-Label, Follow-Up Trial
C. Trenkwalder,1 D. Garcia-Borreguero,2 W. Poewe,3 E. Schollmayer,4 W. Oertel.5   1Paracelsus-Elena Hospital, Kassel, Germany; 2Universidad Autónoma de Madrid, Madrid, Spain; 3Medical University Innsbruck, Innsbruck, Austria, 4SCHWARZ Biosciences, Monheim, Germany; 5Philipps-Universität Marburg, Marburg, Germany.

Poster 35 (PD)
Long-Term Safety of Rotigotine Transdermal Patch in Early-Stage Parkinson’s Disease
R.L. Watts, ¹ R Pahwa,2 K.E. Lyons, 2  B. Boroojerdi. 3  1University of Alabama, Birmingham, AL, USA; 2University of Kansas Medical Center, Kansas City, KS, USA; 3SCHWARZ BIOSCIENCES, Monheim, Germany.

Poster 36 (PD)
Longitudinal Pattern of Cognitive Deficits Associated with Psychotic Symptoms in Parkinson’s Disease
J.R. Williams,1,3 S. Bassett,2,3 T. Dawson,2,3 L. Marsh.2,3  1Bloomberg School of Public Health, Baltimore, MD; 2Bloomberg School of Medicine, Baltimore, MD; 3Morris K. Udall Parkinson’s Disease Research Center of Excellence, The Johns Hopkins University, Baltimore, MD, USA.

Poster 37 (OMD)
LATE-BREAKING RESEARCH                      
The UHDRS Motor Exam and Speeded Tapping in the PREDICT-HD Cohort
C. A. Ross,1 K. Biglan,2 J. C. Stout,3 S. Queller,3 N. Carlozzi,3 K. Duff,4 L.J. Beglinger,4 D.R. Langbehn,4 J.S. Paulsen,4 & the PREDICT-HD Investigators of the Huntington Study Group.  1Johns Hopkins University, Baltimore, MD; 2University of Rochester, Rochester, NY; 3University of Indiana, Bloomington, IN, USA; 4University of Iowa, Iowa City, IA, USA.

Poster 38 (PD)
LATE-BREAKING RESEARCH
Survey of the Parkinson’s Disease Registry
E.R. Dorsey,1 C.A. Beck,1 M.A. Coles,2 R.S. Burns,2 K.M. Biglan.1   1University of Rochester Medical Center, Rochester, NY; 2Muhammad Ali Parkinson Center, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA.

Poster 39 (PD)
LATE-BREAKING RESEARCH
Multi-Center Trial of Tasmar in Parkinson’s Disease: Real-World Experience
K. Sethi,1 S. Factor,2 R. Watts.3   1Medical College of Georgia, Augusta, GA; 2Emory University, Atlanta, GA; 3University of Alabama at Birmingham, Birmingham, AL, USA.

PSG OVERVIEW | PARKINSON'S DISEASE OVERVIEW | WHAT IS A CLINICAL TRIAL

CLINICAL TRIALS IN PROGRESS

COMPLETED CLINICAL TRIALS | PSG / MDS SYMPOSIA | PUBLICATIONS / ABSTRACTS

CONTRIBUTIONS | OTHER USEFUL LINKS